Tech Company Financing Transactions
Omicia Funding Round
Omicia closed a $23 million Series B funding round on 6/8/2016. Backers included Acadia Woods Ventures, ARTIS Ventures and Buchanan Ventures.
Transaction Overview
Company Name
Announced On
6/8/2016
Transaction Type
Venture Equity
Amount
$23,000,000
Round
Series B
Investors
Proceeds Purpose
Omicia's latest financing will be used to fuel acceleration in product development and an expansion in sales, sales support, marketing and operations. In addition, the company plans to extend variations of its flagship OpalTM Clinical platform for use in new geographies and new verticals including life science research, clinical trial support, population health management and consumer applications.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1625 Clay St. 2nd Floor
Oakland, CA 94612
USA
Oakland, CA 94612
USA
Phone
Website
Email Address
Overview
Omicia is unlocking the potential of personalized medicine. Our mission is to help researchers and clinicians understand and apply the most relevant information from personal genome sequences, to improve disease management and medical outcomes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Matt Tindall
Chief Medical Officer
Paul Billings
Chief Operating Officer
Adam Grant
Chief Scientific Officer
Martin Reese
Chief Technical Officer
Edward Kiruluta
VP - Product Management
Charlene Rigby
Browse more venture capital transactions:
Prev: 6/8/2016: Amplitude venture capital transaction
Next: 6/8/2016: RetraceHealth venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on all VC transactions involving tech companies. All VC database entries reported here come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs